Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Vall d'Hebron University Hospital, Barcelona, Spain

Survival: 16.5 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Spain
City/State/Province: Barcelona
Hospital: Vall d'Hebron University Hospital
Journal: Link
Date: 8/2005

Patients: This Phase II study involved 31 women with advanced or metastatic breast cancer. The median age was 57 years. Metastatic sites included skin, bone, soft tissue, and lymph nodes. Nineteen patients had previously received first-line chemotherapy and 10 patients had received second-line chemotherapy. The majority of patients had previously received hormone therapy or trastuzumab in addition to chemotherapy.

Treatment: The treatment consisted of one chemotheraputic agent: gefitinib.

Toxicity: Grade 3-4 toxicities included skin rash and diarrhea. Grade 1-2 toxicities included gastrointestinal and skin disorders.

Results: No complete or partial responses were observed. The median overall survival was 16.5 months (503 days).

Support: One author is an employee of AstraZeneca, and one author has received honoraria from AstraZeneca, Roche, and Merck. AstraZeneca manufactures and markets gefitinib.

Correspondence: Klaus Mrossi, MD

E-mail to a Friend Email Physician More Information